Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × bafetinib × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2 Lymphoid 2 Sarcoma 1 Myeloid 1 Genitourinary 1 CNS 1

Conditions

Hormone Refractory Prostate Cancer 1

Interventions

Docetaxel 187 Prednisone 137 enzalutamide 113 Radiotherapy 107 Gemcitabine 107 Sunitinib 95 Leuprolide 90 Cisplatin 86 pembrolizumab 84 Abiraterone Acetate 84 Nivolumab 80 bicalutamide 76 Paclitaxel 75 Goserelin 72 Sorafenib 68 Carboplatin 67 Everolimus 66 Bevacizumab 58 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 57 Magnetic Resonance Spectroscopy 57 pazopanib 51 Ipilimumab 45 radium Ra 223 dichloride 43 Zoledronic Acid 41 Radiosurgery 41 Cyclophosphamide 40 Filgrastim 37 aldesleukin 35 cabozantinib 34 apalutamide 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01215799 2011-12-15

PROACT

CytRx

Phase 2 Completed

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡